

4e Multidisciplinair Immuno-Oncologie Symposium	
Tuesday 18 September 2018, Driebergen, The Netherlands	
Programme	
13.30	Registration
Plenary session 1	
14.00	Tumor heterogeneity influences the immune system's ability to fight cancer <i>Samra Turajlic, The Francis Crick Institute, London, UK</i>
14.30 - 15.45	Parallel session1
	Medical Oncology
14.30	Merkel cell carcinoma: what can we do with Immunotherapy? <i>Jurgen Becker, dermatologist, Group for Translational Skin Cancer Research, Heidelberg, Germany</i>
14.55	T-VEC in stadium IIIc melanoom <i>Viola Franke, arts-onderzoeker afdeling Chirurgisch Oncologie, NKI-AvL, Amsterdam</i>
15.20	Melanoma: when to stop immuno therapy? <i>Bart Neyns, medisch oncoloog, UZ Brussel, Belgie</i>
15.45 - 16.15	Break
Plenary session 2	
16.15	Case 2 Management immuno therapie related toxicity <i>Karlijn Suijkerbuijk, medisch oncoloog, UMCU</i>
16.45	Hoe kunnen wij CAR-T cel therapie effectiever en veiliger maken? <i>Maria Themeli, assistant professor, Cancer Center Amsterdam m.themeli@vumc.nl</i>
17.15	Stop & go prospective trial met immunotherapy <i>Astrid van der Veldt, medisch oncoloog, ErasmusMC</i>
17.45 - 19.00	Walking dinner
19.00	In situ cancer vaccines: tumor ablation and immunotherapy <i>Gosse Adema, Dept. Molecular Immunology Radiotherapy & Oncimmunology Laboratory, Radboudumc Gosse.Adema@radboudumc.nl</i>
19.30	Non-invasive imaging-based biomarkers? <i>Regina Beets-Tan, radiologist, NKI-AvL, Amsterdam j.tuurenhout@nki.nl (secr) r.beetstan@nki.nl</i>
20.00	Closure